Table 1 Relationship between fascin and MMP-9 expressions and clinicopathological parameters of the studied breast carcinomas (n = 67)
| Â | Fascin expression | MMP-9 expression | |||||
|---|---|---|---|---|---|---|---|
Variable | n (%) | Negative n = 38 | Positive n = 29 | P value | Negative n = 33 | Positive n = 33 | P value |
Age (years) | Â | Â | Â | Â | Â | Â | Â |
≤ 50 | 22 (33) | 10 (45.5%) | 12 (54.5%) | 0.193* | 10 (45.5%) | 12 (54.5%) | 0.664* |
>50 | 45 (67) | 28 (62.2%) | 17 (37.8%) | (NS) | 23 (51.1%) | 22 (48.9%) | (NS) |
Tumor size (cm) | Â | Â | Â | Â | Â | Â | Â |
≤5 | 41 (61.19) | 27 (65.9%) | 14 (34.1%) | 0.058* | 24 (58.5%) | 17 (41.5%) | 0.056* |
>5 | 26 (38.81) | 11 (42.3%) | 15 (57.7%) | (NS) | 9 (34.6%) | 17 (65.4%) | (NS) |
Grades | Â | Â | Â | Â | Â | Â | Â |
I | 7 (10.4) | 3 (42.9%) | 4 (57.1%) | 0.111** | 2 (28.6%) | 5 (71.4%) | 0.088** |
II | 44 (65.7) | 29 (65.9%) | 15 (34.1%) | (NS) | 26 (59.1%) | 18 (40.9%) | (NS) |
III | 16 (23.9) | 6 (37.5%) | 10 (62.5%) | Â | 5 (31.2%) | 11 (68.8%) | Â |
Lymph nodal status | Â | Â | Â | Â | Â | Â | Â |
Node – | 24 (35.8) | 20 (83.3%) | 4 (16.7%) | 0.001* | 18 (75.0%) | 6 (25.0%) | 0.002* |
Node + | 43 (64.2) | 18 (41.9%) | 25 (58.1%) | (S) | 15 (34.9%) | 28 (65.1%) | (S) |
Stage | Â | Â | Â | Â | Â | Â | Â |
I | 18 (26.87) | 15 (83.3%) | 3 (16.7%) | 0.004* | 14 (77.8%) | 4 (22.2%) | 0.005* |
II | 29 (43.28) | 17 (58.6%) | 12 (41.4%) | (S) | 14 (48.3%) | 15 (51.7%) | (S) |
III | 20 (29.85) | 6 (30.0%) | 14 (70.0%) | Â | 5 (25.0%) | 15 (75.0%) | Â |
Estrogen receptor | Â | Â | Â | Â | Â | Â | Â |
Negative | 21 (31.3) | 6 (28.6%) | 15 (71.4%) | 0.002* | 5 (23.8%) | 16 (76.2%) | 0.005* |
Positive | 46 (68.7) | 32 (69.6%) | 14 (30.4%) | (S) | 28 (60.9%) | 18 (39.1%) | (S) |
Progesterone receptor | Â | Â | Â | Â | Â | Â | Â |
Negative | 24 (35.8) | 7 (29.2%) | 17 (70.8%) | 0.001* | 6 (25.0%) | 18 (75.0%) | 0.003* |
Positive | 43 (64.2) | 31 (72.1%) | 12 (27.9%) | (S) | 27 (62.8%) | 16 (37.2%) | (S) |
HER2 | Â | Â | Â | Â | Â | Â | Â |
Negative | 55 (82.1) | 33 (60.0%) | 22 (40.0%) | 0.246* | 30 (54.5%) | 25 (45.5%) | 0.064* |
Positive | 12 (17.9) | 5 (41.7%) | 7 (58.3%) | (NS) | 3 (25.0%) | 9 (75.0%) | (NS) |